What is the significance of the formation of MapKure, LLC?

The formation of MapKure, LLC, a joint venture with SpringWorks Therapeutics, Inc., is significant because it establishes a dedicated entity to develop BGB-3245, an investigational drug targeting specific BRAF mutations and fusions. This partnership allows BeiGene to leverage SpringWorks' expertise and investment to advance BGB-3245, potentially expanding its reach in the oncology market outside of Asia.

What is BGB-3245 and what cancers could it treat?

BGB-3245 is an investigational, oral, selective small molecule inhibitor discovered by BeiGene scientists. It targets both monomer and dimer forms of activating BRAF mutations, including V600 BRAF mutations, non-V600 B-RAF mutations, and RAF fusions. These genetic alterations are known drivers of cancer growth in several solid tumors, such as non-small cell lung cancer, colorectal cancer, thyroid cancer, and brain tumors.

What were the key clinical updates regarding zanubrutinib?

BeiGene presented clinical data for its investigational BTK inhibitor, zanubrutinib, at the 15th International Conference on Malignant Lymphoma (ICML). This included updated results in mantle cell lymphoma (MCL), pivotal Phase 2 results in relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in China, and Phase 1b results from a combination study of zanubrutinib with obinutuzumab in patients with CLL/SLL or follicular lymphoma (FL).

What is BeiGene's role and ownership in MapKure?

BeiGene discovered BGB-3245 and contributed an exclusive royalty and milestone-bearing license to develop and commercialize it outside of Asia (including Japan) to MapKure. In return, BeiGene received a majority ownership position in the newly formed entity, MapKure, LLC.

ONC/BEIGF 8-K: Regulation FD

Summary

BeOne Medicines Ltd. (ONC) filed an 8-K on June 20, 2019, detailing significant corporate developments and clinical data updates. A key announcement was the formation of MapKure, LLC, a joint venture with SpringWorks Therapeutics, Inc., to develop BGB-3245, an investigational oral selective small molecule inhibitor targeting various BRAF mutations and fusions in solid tumors. BeiGene will retain a majority ownership in MapKure and has licensed BGB-3245 for development and commercialization outside of Asia (excluding Japan). This strategic partnership aims to advance a promising oncology candidate with broad potential across multiple cancer types. In addition to the MapKure formation, the company presented important clinical data for its Bruton's tyrosine kinase (BTK) inhibitor, zanubrutinib, at the 15th International Conference on Malignant Lymphoma (ICML). Updates included results from studies in mantle cell lymphoma (MCL), relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China, and a Phase 1b study evaluating zanubrutinib in combination with obinutuzumab for CLL/SLL and follicular lymphoma (FL). These presentations highlight the ongoing progress and clinical validation of zanubrutinib across different hematological malignancies.

Key Highlights

1Formation of MapKure, LLC, a joint venture with SpringWorks Therapeutics, Inc., to develop BGB-3245, an investigational RAF inhibitor.
2BGB-3245 targets specific BRAF mutations and fusions implicated in various solid tumors, including non-small cell lung cancer and colorectal cancer.
3BeiGene retains majority ownership in MapKure and has exclusive rights for BGB-3245 outside of Asia (excluding Japan).
4Presentation of clinical data updates for zanubrutinib, an investigational BTK inhibitor, at the 15th International Conference on Malignant Lymphoma (ICML).
5Data presented on zanubrutinib in mantle cell lymphoma (MCL), relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.
6Results from a Phase 1b study of zanubrutinib in combination with obinutuzumab for CLL/SLL and follicular lymphoma (FL) were also shared.
7Company hosted an investor conference call and webcast on June 20, 2019, to discuss mid-2019 clinical data updates.

BeOne Medicines Ltd. 8-K Report, Regulation FD Disclosure (Jun 20, 2019)

Summary

Key Highlights

Frequently Asked Questions